Agitation in Alzheimer's Disease Market Size to Witness Significant Growth During the Forecast Period

Strategic Insights -

The Alzheimer's disease market, particularly the agitation subset, is expected to experience a substantial increase in market size, primarily driven by the aging population, especially in developed countries where Alzheimer's disease prevalence is higher. Emerging therapies, such as TransCon hGH, HyTropin (GX-H9), Somatrogon, and others, are anticipated to drive significant growth in the market over the coming years. The Agitation in Alzheimer's Disease market is expected to grow at a steady CAGR from 2024 to 2034, largely driven by the rising aging population, especially in developed nations where Alzheimer's prevalence is higher.

Key Takeaways:

  • The Agitation in Alzheimer's Disease market report delivers an in-depth understanding of the Agitation in Alzheimer's Disease, historical and forecasted epidemiology as well as the Agitation in Alzheimer's Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The Agitation in Alzheimer's Disease market is projected to grow at a steady CAGR from 2024 to 2034, largely driven by the rising aging population, especially in developed nations where Alzheimer's prevalence is higher.
  • Epidemiological data highlights agitation as a common manifestation in Alzheimer's disease, though prevalence varies due to differences in diagnostic criteria and study methodologies.
  • Management of agitation in Alzheimer's is challenging due to its multifactorial origins, and targeted medications and therapeutic strategies are used to ease symptoms and enhance overall quality of life.
  • Current strategies often rely on antipsychotic medications, but they are linked to risks including sedation, metabolic complications, and a higher risk of strokes in older adults.
  • Non-pharmacological interventions like music therapy, aromatherapy, and structured daily routines play an important role in reducing aggression, and offer safer alternatives.
  • Commonly prescribed medications include risperidone, quetiapine, aripiprazole, carbamazepine, citalopram, gabapentin, prazosin, trazodone, lorazepam, and cyproterone acetate, which may help control symptoms but also pose risks such as falls, sedation, and metabolic side effects.
  • REXULTI (brexpiprazole) is the only FDA-approved therapy for agitation linked to Alzheimer's dementia.
  • Emerging therapies, such as AXS-05, AVP-786, and BXCL501, are being developed to target dopamine and serotonin receptors, helping to alleviate behavioral disturbances.
  • BioXcel Therapeutics, Inc. reported that the U.S. FDA had completed the inspection of a trial site involved in its TRANQUILITY II Phase 3 study under 21 C.F.R. 20.64(d)(3), issuing the Establishment Inspection Report.
  • The Agitation in Alzheimer's Disease market report provides insights on the current and emerging therapies, offering a global historical and forecasted market covering drug outreach in 7MM.

Statistics:

  • The Agitation in Alzheimer's Disease market size is projected to experience a consistent CAGR during the forecast period (2024-2034).
  • The Agitation in Alzheimer's Disease market is expected to grow at a steady CAGR from 2024 to 2034, largely driven by the rising aging population, especially in developed nations where Alzheimer's prevalence is higher.
  • In Europe, the prevalence of agitation among Alzheimer's patients has been reported to range between 24% and 88% (Source: https://www.abnewswire.com/pressreleases/Agitation-in-Alzheimer-s-Disease-Market-to-Experience-Significant-Growth-2034.html).
  • The Agitation in Alzheimer's Disease market is expected to be driven by emerging therapies, such as TransCon hGH, HyTropin (GX-H9), Somatrogon, and others (Source: https://www.abnewswire.com/pressreleases/Agitation-in-Alzheimer-s-Disease-Market-to-Experience-Significant-Growth-2034.html).
  • The U.S. FDA had completed the inspection of a trial site involved in BioXcel Therapeutics, Inc.'s TRANQUILITY II Phase 3 study (Source: https://www.abnewswire.com/pressreleases/Agitation-in-Alzheimer-s-Disease-Market-to-Experience-Significant-Growth-2034.html).

Sources:

  • M2 PRESSWIRE-August 26, 2025-: Agitation in Alzheimer's Disease Market: Epidemiology, Pipeline, Companies Working, DelveInsight | Eli Lilly and Co, BioVie Inc, AB Science SA, Annovis Bio Inc, Cognition Therapeutics Inc, Coya Therap
  • https://www.delveinsight.com/report-store/agitation-in-alzheimer-disease?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
  • www.abnewswire.com ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.m2.co.uk on the world wide web. Inquiries to info@m2.co.uk)).